Immuse
For Manufacturers  
Menu
Contact
  • About IMMUSE™
    • Immune System 101
    • What is a Postbiotic?
    • Consumer FAQs
  • Benefits
    • Immune Support
    • Sports Nutrition Support
    • Productivity Support
  • Science & Research
    • Vital Role of pDCs
  • Where to Find
  • News & Blog
    • Blog
  • Contact Us

IMMUSE™ News

  • Well Traveled Releases a Novel Travel Supplement Featuring IMMUSE™

    12 April 2023 PRWeb.com

    Kyowa Hakko’s IMMUSE™, a research-backed postbiotic, provides immune support for travelers in this new innovative formula, “Well Traveled Immune Activator." Read More ›

  • Comple.med Launches the First Food Supplement in Europe Featuring IMMUSE®

    01 February 2023 MILAN, ITALY

    Kyowa Hakko’s IMMUSE®, a clinically researched unique postbiotic, provides immune support in Lactoflor® Immuno 200 . Read More ›

  • Kyowa Hakko Announces Glaxon’s Limited-Time Offer Becomes A Permanent Feature

    26 October 2022

    After a resoundingly successful limited-time offering, Glaxon™ has now added Kyowa Hakko’s IMMUSE™ to all SuperGreens Immune formulas. Read More ›

    immune health, functional foods, postbiotics, SuperGreens
  • Kyowa Hakko USA Announces the Appointment of Dr. Colin Hill to the Scientific Advisory Board of Award-Winning Postbiotic IMMUSE™

    19 May 2022 PRWeb.com

    With an impressive background in mining the microbiome for novel therapies, Prof. Hill helped with the definition of a postbiotic as a part of ISAPP. Read More ›

  • Kyowa Hakko USA Announces the Appointment of Dr. Heather Moday as an Educational Partner for IMMUSE™ LC-Plasma

    12 May 2022 PRWeb.com

    With a special interest in immune system dysfunction, including autoimmunity, allergy, and the stress-immune connection, Dr. Moday puts IMMUSE™, an award-winning postbiotic, at the forefront of ingredients to look out for in nutritional supplements. Read More ›

  • Kyowa Hakko Announces the Results of Three New Consumer Surveys on Consumer Preferences

    15 December 2021 PRWeb.com

    New consumer surveys reveal supplement users prefer branded ingredients 2x over generic ingredients when making purchasing decisions. Read More ›

  • Kyowa Hakko USA Awarded Best-In-Class Ingredient by Natural Products Insider's Ingredient Idol for its Immune Support Postbiotic, IMMUSE™

    16 November 2021

    Highlighted at the Annual Supply Side West Conference, the Function of Kyowa Hakko’s Novel Postbiotic was recognized as a leader for Immune Health. Read More ›

  • iMUSE Wins 2021 Product of the Year Award in the Immune Support Category at the Nutralngredients-Asia Awards

    30 September 2021

    Kirin Holdings Company, Limited's (Kirin Holdings) iMUSE brand (IMMUSE in some markets), won the 2021 Product of the Year Award in the Immune Support category of the Nutralngredients-Asia Awards, held by William Reed Business Media (WRBM), a leading publisher of digital newsletters, publications and data sources for the food, beverage and nutrition industries worldwide. Read More ›

  • Kyowa Hakko Acclaimed by Frost & Sullivan for its Non-GMO, Allergen-free, Immune Support Paraprobiotic Ingredient, IMMUSE™

    21 September 2021

    The solution offers superior ease of formulation, potential application versatility, and more comprehensive immune support compared to probiotics and other immune health ingredients. Read More ›

  • Kirin Holdings to Double Lactococcus Lactis Strain Plasma Production

    09 September 2021

    Kirin Holdings Company, Limited (Kirin Holdings) announces that it will expand manufacturing equipment at the iMUSE Health Science Factory (located in Saitama Prefecture, just north of Tokyo) - a manufacturing center for lactic acid bacteria raw material - in order to meet the increasing demand for Kirin's proprietary Lactococcus lactis strain Plasma (L. lactis strain Plasma), the functional ingredient in the popular iMUSE brand of immune maintenance products. The new manufacturing equipment is scheduled to begin operating in 2023, and will double the annual production capacity of L. lactis strain Plasma to approximately 28 tons in 2023. Read More ›

  • 1
  • 2
  • Next →

Interested in IMMUSE? Subscribe to updates.

Subscribe to updates Subscribe for updates
Find Products
Find Products Find products that contain IMMUSE
Find Products Find products that contain IMMUSE
Kirin logo      Kyowa logo
Home | Get News Alerts | News | Where to Find | Privacy Policy | Kyowa Hakko USA | Kyowa Hakko Bio | Kirin Holdings | Contact Us | Kyowa Partner Toolkit

IMMUSE™ is a clinically researched lactic acid bacteria developed by Kirin Holdings Co., Ltd.

Copyright © 2010-2023 by All Rights Reserved. | AWS

* These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.